Prediction of Genetic Alterations in Oncogenic Signaling Pathways in Squamous Cell Carcinoma of the Head and Neck: Radiogenomic Analysis Based on Computed Tomography Images

Overview

Journal J Comput Assist Tomogr

Specialty Radiology

Date 2021 Sep 1

PMID 34469904

Authors

Linyong Wu

Peng Lin

Yujia Zhao

Xin Li

Hong Yang

Yun He

Affiliations

Soon will be listed here.

Abstract

Objective: This study investigated the role of radiomics in evaluating the alterations of oncogenic signaling pathways in head and neck cancer.

Methods: Radiomics features were extracted from 106 enhanced computed tomography images with head and neck squamous cell carcinoma. Support vector machine-recursive feature elimination was used for feature selection. Support vector machine algorithm was used to develop radiomics scores to predict genetic alterations in oncogenic signaling pathways. The performance was evaluated by the area under the curve (AUC) of the receiver operating characteristic curve.

Results: The alterations of the Cell Cycle, HIPPO, NOTCH, PI3K, RTK RAS, and TP53 signaling pathways were predicted by radiomics scores. The AUC values of the training cohort were 0.94, 0.91, 0.94, 0.93, 0.87, and 0.93, respectively. The AUC values of the validation cohort were all greater than 0.7.

Conclusions: Radiogenomics is a new method for noninvasive acquisition of tumor molecular information at the genetic level.

References

Zhou K, Chen J, Wu J, Xu Y, Wu Q, Yue J . Profilin 2 Promotes Proliferation and Metastasis of Head and Neck Cancer Cells by Regulating PI3K/AKT/β-Catenin Signaling Pathway. Oncol Res. 2019; 27(9):1079-1088. PMC: 7848265. DOI: 10.3727/096504019X15579146061957. View

Alderson P, Summers R . The Evolving Status of Radiomics. J Natl Cancer Inst. 2020; 112(9):869-870. PMC: 7492766. DOI: 10.1093/jnci/djaa018. View

Li Y, Song X, Liu M, Wang B, Zhang J, Li A . Multimodal Device and Computer Algorithm-Based Monitoring of Pancreatic Microcirculation Profiles In Vivo. Pancreas. 2020; 49(8):1075-1082. PMC: 7447165. DOI: 10.1097/MPA.0000000000001627. View

Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439(7074):353-7. DOI: 10.1038/nature04296. View

Poma A, Torregrossa L, Bruno R, Basolo F, Fontanini G . Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature. Sci Rep. 2018; 8(1):10623. PMC: 6045671. DOI: 10.1038/s41598-018-28928-3. View

Zwanenburg A, Vallieres M, Abdalah M, Aerts H, Andrearczyk V, Apte A . The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020; 295(2):328-338. PMC: 7193906. DOI: 10.1148/radiol.2020191145. View

Lien E, Lyssiotis C, Juvekar A, Hu H, Asara J, Cantley L . Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nat Cell Biol. 2016; 18(5):572-8. PMC: 4848114. DOI: 10.1038/ncb3341. View

Zhai T, Langendijk J, van Dijk L, van der Schaaf A, Sommers L, Vemer-van den Hoek J . Pre-treatment radiomic features predict individual lymph node failure for head and neck cancer patients. Radiother Oncol. 2020; 146:58-65. DOI: 10.1016/j.radonc.2020.02.005. View

Anastas J, Moon R . WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2012; 13(1):11-26. DOI: 10.1038/nrc3419. View

10.

Tian X, Su N, Wang L, Huang W, Liu Y, Zhang X . A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma. Clin Cancer Res. 2020; 26(14):3760-3770. DOI: 10.1158/1078-0432.CCR-19-4207. View

11.

Obenauf A, Zou Y, Ji A, Vanharanta S, Shu W, Shi H . Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015; 520(7547):368-72. PMC: 4507807. DOI: 10.1038/nature14336. View

12.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

13.

Hoxhaj G, Manning B . The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2019; 20(2):74-88. PMC: 7314312. DOI: 10.1038/s41568-019-0216-7. View

14.

Katsoulakis E, Yu Y, Apte A, Leeman J, Katabi N, Morris L . Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. Oral Oncol. 2020; 110:104877. PMC: 7606635. DOI: 10.1016/j.oraloncology.2020.104877. View

15.

Bi W, Hosny A, Schabath M, Giger M, Birkbak N, Mehrtash A . Artificial intelligence in cancer imaging: Clinical challenges and applications. CA Cancer J Clin. 2019; 69(2):127-157. PMC: 6403009. DOI: 10.3322/caac.21552. View

16.

Wang H, Sun B, Zhu Z, Chang E, To K, Hwang J . Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. J Clin Oncol. 2011; 29(34):4516-25. DOI: 10.1200/JCO.2010.33.7741. View

17.

Grossmann T, Yeh J, Bowman B, Chu Q, Moellering R, Verdine G . Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin. Proc Natl Acad Sci U S A. 2012; 109(44):17942-7. PMC: 3497784. DOI: 10.1073/pnas.1208396109. View

18.

Wang K, Zhou Z, Wang R, Chen L, Zhang Q, Sher D . A multi-objective radiomics model for the prediction of locoregional recurrence in head and neck squamous cell cancer. Med Phys. 2020; 47(10):5392-5400. DOI: 10.1002/mp.14388. View

19.

Yuan T, Cantley L . PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008; 27(41):5497-510. PMC: 3398461. DOI: 10.1038/onc.2008.245. View

20.

Zhang F, Liu Y, Yang Y, Yang K . Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma. BMC Cancer. 2020; 20(1):1015. PMC: 7574345. DOI: 10.1186/s12885-020-07489-7. View